Compare · BON vs DFTX
BON vs DFTX
Side-by-side comparison of Bon Natural Life Limited (BON) and Definium Therapeutics Inc. (DFTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BON and DFTX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $2.57B, about 252.8x BON ($10.2M).
- Over the past year, BON is down 24.2% and DFTX is up 194.7% - DFTX leads by 218.9 points.
- DFTX has hit the wire 3 times in the past 4 weeks while BON has been quiet.
- DFTX has more recent analyst coverage (4 ratings vs 0 for BON).
PerformanceBON-24.24%DFTX+189.80%
2025-06-09+0.00%2026-06-05
- Company
- Bon Natural Life Limited
- Definium Therapeutics Inc.
- Price
- $1.25+0.81%
- $22.88-2.89%
- Market cap
- $10.2M
- $2.57B
- 1M return
- -0.79%
- -1.55%
- 1Y return
- -24.24%
- +194.66%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 0
- 3
- Recent ratings
- 0
- 4
Latest BON
- SEC Form 3 filed by new insider Zhixiang Gao
- SEC Form 3 filed by new insider Chen Jing Veronica
- SEC Form 3 filed by new insider Hu Yongwei
- SEC Form 3 filed by new insider Xue Yingchun
- SEC Form 3 filed by new insider Ma Xin
- SEC Form 3 filed by new insider Wenjuan Chen
- SEC Form 3 filed by new insider Liu Jing
- SEC Form 3 filed by new insider Gao Jianjun
- BON Unveils Strategic Partnership with Tigerbone Group to Launch New Natural Health Initiatives
- SEC Form 6-K filed by Bon Natural Life Limited
Latest DFTX
- Definium Therapeutics Announces New Employee Inducement Grants
- Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
- Definium Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Definium Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder
- Definium Therapeutics Announces New Employee Inducement Grants
- SEC Form 10-Q filed by Definium Therapeutics Inc.
- Definium Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
- Definium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026